Mainz Biomed (MYNZ)

• Market cap: $7.36M
• 1 day: -4.23%
• 5 days: -8.11%
• 1 month: -16.05%
• 3 months: -7.48%
• 6 months: -44.26%
• Year to date: -68.37%
• 1 year: -84.55%
• 5 years: -99.66%
• 10 years: -99.66%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Employees: 26